KR20220017917A - Thr-베타의 조절제 및 이의 사용 방법 - Google Patents

Thr-베타의 조절제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20220017917A
KR20220017917A KR1020217039735A KR20217039735A KR20220017917A KR 20220017917 A KR20220017917 A KR 20220017917A KR 1020217039735 A KR1020217039735 A KR 1020217039735A KR 20217039735 A KR20217039735 A KR 20217039735A KR 20220017917 A KR20220017917 A KR 20220017917A
Authority
KR
South Korea
Prior art keywords
optionally substituted
group
alkyl
tautomer
compound
Prior art date
Application number
KR1020217039735A
Other languages
English (en)
Korean (ko)
Inventor
쾬 반다이크
?? 반다이크
피에르 장-마리 베르나르 라부아쏜
데이비드 맥고원
제롬 드발
Original Assignee
알리고스 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알리고스 테라퓨틱스 인코포레이티드 filed Critical 알리고스 테라퓨틱스 인코포레이티드
Publication of KR20220017917A publication Critical patent/KR20220017917A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217039735A 2019-05-08 2020-05-07 Thr-베타의 조절제 및 이의 사용 방법 KR20220017917A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962845252P 2019-05-08 2019-05-08
US62/845,252 2019-05-08
US201962944052P 2019-12-05 2019-12-05
US62/944,052 2019-12-05
US202063005661P 2020-04-06 2020-04-06
US63/005,661 2020-04-06
PCT/US2020/031904 WO2020227549A1 (fr) 2019-05-08 2020-05-07 MODULATEURS DE THR-β ET LEURS PROCÉDÉS D'UTILISATION

Publications (1)

Publication Number Publication Date
KR20220017917A true KR20220017917A (ko) 2022-02-14

Family

ID=70919081

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217039735A KR20220017917A (ko) 2019-05-08 2020-05-07 Thr-베타의 조절제 및 이의 사용 방법

Country Status (16)

Country Link
US (2) US11091467B2 (fr)
EP (1) EP3965884A1 (fr)
KR (1) KR20220017917A (fr)
CN (1) CN114096531A (fr)
AU (1) AU2020267576A1 (fr)
BR (1) BR112021021718A2 (fr)
CA (1) CA3139101A1 (fr)
CL (1) CL2021002883A1 (fr)
CO (1) CO2021015698A2 (fr)
GE (1) GEP20247637B (fr)
IL (1) IL287720A (fr)
MA (1) MA55890A (fr)
MX (1) MX2021013472A (fr)
PE (1) PE20220255A1 (fr)
SG (1) SG11202111552YA (fr)
WO (1) WO2020227549A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220017917A (ko) * 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
WO2021104288A1 (fr) * 2019-11-26 2021-06-03 昆药集团股份有限公司 Composé de 1,2,4-triazine-3,5-dione, son procédé de préparation et son utilisation
WO2021129465A1 (fr) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 Cristal de resmétirom, son procédé de préparation et ses utilisations
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
CN116171275A (zh) * 2020-09-10 2023-05-26 苏州科睿思制药有限公司 Resmetirom的晶型及其制备方法和用途
WO2022053028A1 (fr) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 Composé de 1,2,4-triazine-3,5-(2h,4h)-dicétone et son utilisation
EP4215524A4 (fr) * 2020-09-17 2024-10-02 Sunshine Lake Pharma Co Ltd Composé servant d'agoniste du récepteur beta de l'hormone thyroïdienne et utilisations du composé
TW202233577A (zh) 2020-11-06 2022-09-01 美商艾利格斯醫療公司 羥吲哚及其使用方法
AU2021376281A1 (en) * 2020-11-06 2023-06-15 Aligos Therapeutics, Inc. Pyridazinone derivatives as thyroid receptor agonists and uses thereof
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
US20240059682A1 (en) * 2021-03-03 2024-02-22 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
WO2022242743A1 (fr) * 2021-05-21 2022-11-24 深圳微芯生物科技股份有限公司 Composé hétérocyclique et son application
WO2023023474A1 (fr) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Modulateurs du tr-bêta, compositions pharmaceutiques et applications thérapeutiques
KR20240112993A (ko) 2021-09-01 2024-07-19 알리고스 테라퓨틱스 인코포레이티드 Pnpla3-표적화 짧은 간섭 rna(sirna) 분자 및 이의 용도
AU2022343115A1 (en) 2021-09-08 2024-03-14 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途
WO2024182446A2 (fr) 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Molécules d'arn interférent court (arnsi) ciblant pnpla3 et leurs utilisations
WO2024187038A1 (fr) 2023-03-07 2024-09-12 Aligos Therapeutics, Inc. Molécules d'acide nucléique interférent court (sina) modifiées et leurs utilisations

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
DK1088819T3 (da) 1999-09-30 2005-09-12 Pfizer Prod Inc 6-azauracilderivater som thyroidreceptorligander
DK1262177T3 (da) 2001-05-31 2006-11-20 Pfizer Prod Inc Medicinsk brug af thyromimetiske forbindelser til behandling af hårtab og kompositioner
US7230031B2 (en) 2002-01-30 2007-06-12 Kissei Pharmaceutical Co., Ltd. Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
DE60330466D1 (de) 2002-07-29 2010-01-21 Rigel Pharmaceuticals Inc VERFAHREN ZUR BEHANDLUNG ODER PRuVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
AU2003278544A1 (en) 2002-11-25 2004-06-18 Pfizer Products Inc. Method for promoting nail growth using thyromimetic compounds
PT1919878E (pt) * 2005-07-21 2010-11-02 Hoffmann La Roche Derivados de piridazinona como agonistas do receptor da hormona da tiróide
JP2009521448A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
KR20090025367A (ko) * 2006-06-28 2009-03-10 가부시키가이샤산와카가쿠켄큐쇼 신규 6-5계 이환식 복소환 유도체 및 그 의약용도
WO2008104752A1 (fr) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropytidones inhibiteurs d'élastase
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
AU2010240200B2 (en) * 2009-04-20 2014-03-13 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone beta receptor agonist
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
PL2695611T3 (pl) 2012-08-06 2015-03-31 Dr August Wolff Gmbh & Co Kg Arzneimittel Eprotirom do stosowania w profilaktyce i/lub leczeniu zaburzeń włosów oraz jego kompozycje
KR20200023528A (ko) 2012-09-17 2020-03-04 마드리갈 파마슈티칼스, 인크. 갑상선 호르몬 유사체 및 이의 다형의 합성 방법
ES2680550T3 (es) 2013-07-09 2018-09-10 Bristol-Myers Squibb Company Combinaciones de inhibidores del virus de la hepatitis C
US10303567B2 (en) 2013-08-15 2019-05-28 Entit Software Llc Managing database nodes
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
EA201892625A1 (ru) 2015-01-09 2019-07-31 Джилид Аполло, Ллс КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
KR102444366B1 (ko) 2016-06-03 2022-09-19 케모센트릭스, 인크. 간 섬유화 치료 방법
US11090308B2 (en) 2016-10-18 2021-08-17 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a THR-beta agonist
BR112019018162A2 (pt) 2017-03-13 2020-04-07 Genfit Composições farmacêuticas para terapia de combinação
WO2018193007A1 (fr) 2017-04-18 2018-10-25 Genfit Combinaison comprenant un agoniste de ppar tel qu'elafibranor et un inhibiteur de l'acétyl-coa carboxylase (acc)
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
CN111183360B (zh) 2017-07-19 2024-10-18 生物辐射欧洲有限公司 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合
WO2019099457A1 (fr) 2017-11-14 2019-05-23 Quixgen, Inc. Composés de benzodioxinone
CA3084728A1 (fr) 2017-12-06 2019-06-13 Basf As Derives d'acide gras pour le traitement de la steatohepatite non alcoolique
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
WO2019178023A1 (fr) 2018-03-12 2019-09-19 Yale University Procédés de traitement ou de prévention du syndrome de détresse respiratoire aiguë
EP3787618A4 (fr) 2018-05-04 2022-05-04 Cirius Therapeutics, Inc. Analogues de thiazolidinedione pour le traitement de nafld et de maladies métaboliques
CN108727344A (zh) 2018-05-14 2018-11-02 嘉兴特科罗生物科技有限公司 一种化合物及其合成方法和应用
CN111801324B (zh) * 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
WO2019239436A1 (fr) 2018-06-14 2019-12-19 Alma Mater Studiorum - Universita' Di Bologna Fibres électrofilées pour une libération locale d'un médicament anti-inflammatoire et d'un médicament promyélinisant
CN110627773B (zh) 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
TW202019914A (zh) 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
MA53448A (fr) 2018-08-24 2022-04-20 Terns Inc Composés agonistes des récepteurs bêta des hormones thyroïdiennes
CN112739692A (zh) * 2018-10-12 2021-04-30 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
TWI840423B (zh) 2018-10-12 2024-05-01 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
JP7445996B2 (ja) 2019-02-21 2024-03-08 ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド 新規化合物及び甲状腺ホルモン受容体アゴニストとしてのそれらの使用
KR20220017917A (ko) * 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
CN111909137B (zh) 2019-05-10 2023-05-30 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
IT201900006923A1 (it) 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
CN112300133B (zh) 2019-07-31 2024-07-30 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
WO2021032218A1 (fr) 2019-08-19 2021-02-25 苏州闻天医药科技有限公司 COMPOSÉ AGONISTE DU RÉCEPTEUR THR-β HÉTÉROCYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
WO2021041237A1 (fr) 2019-08-23 2021-03-04 Terns, Inc. Composés agonistes du récepteur bêta de l'hormone thyroïdienne
CN112442013B (zh) 2019-09-04 2022-07-26 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
JP2022548250A (ja) 2019-09-12 2022-11-17 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
US20220411400A1 (en) 2019-09-24 2022-12-29 Sunshine Lake Pharma Co., Ltd. Chemical compound as thyroid hormone beta receptor agonist and use thereof

Also Published As

Publication number Publication date
AU2020267576A1 (en) 2021-12-09
EP3965884A1 (fr) 2022-03-16
MX2021013472A (es) 2022-01-06
CA3139101A1 (fr) 2020-11-12
MA55890A (fr) 2022-03-16
CN114096531A (zh) 2022-02-25
JP2022532706A (ja) 2022-07-19
US20210355112A1 (en) 2021-11-18
BR112021021718A2 (pt) 2022-01-18
CO2021015698A2 (es) 2022-01-17
TW202108569A (zh) 2021-03-01
WO2020227549A1 (fr) 2020-11-12
WO2020227549A8 (fr) 2021-05-27
IL287720A (en) 2021-12-01
US20200354345A1 (en) 2020-11-12
CL2021002883A1 (es) 2022-10-28
PE20220255A1 (es) 2022-02-16
US11091467B2 (en) 2021-08-17
SG11202111552YA (en) 2021-11-29
GEP20247637B (en) 2024-06-25

Similar Documents

Publication Publication Date Title
KR20220017917A (ko) Thr-베타의 조절제 및 이의 사용 방법
CN109071498B (zh) 激酶抑制剂及其制备方法和用途
WO2021169990A1 (fr) Inhibiteurs de kras pour le traitement de cancers
WO2020259679A1 (fr) Dérivé hétérocyclique azoté à cinq chaînons de pyrimidine, son procédé de préparation et son utilisation pharmaceutique
TWI662026B (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
KR20210042265A (ko) 헌팅턴병 치료를 위한 헤테로사이클릭 및 헤테로아릴 화합물
TWI839363B (zh) 嘧啶化合物及包括其之供預防或治療癌症的藥學組成物
WO2018166493A1 (fr) Dérivé d'hétéroaryl[4,3-c]pyrimidine-5-amine, son procédé de préparation et ses utilisations médicales
WO2022007979A1 (fr) Dérivé d'imidazole condensé, son procédé de préparation et son utilisation médicale
WO2022017339A1 (fr) Dérivé pyridazinique condensé, son procédé de préparation et son utilisation pharmaceutique
WO2020011246A1 (fr) Composé contenant un cycle benzénique, son procédé de préparation et son utilisation
TW201623250A (zh) 作為ｔｒｐｍ８拮抗劑之氮雜螺衍生物
KR20180031823A (ko) 피리다지논, 그의 제조 방법 및 사용 방법
WO2021249519A1 (fr) Dérivé de pyridine-pyrimidine, son procédé de préparation et son utilisation pharmaceutique
TW202317564A (zh) Cdk2抑制劑及其製備方法和用途
CN109071548A (zh) 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物
WO2022028506A1 (fr) Inhibiteur de sos1, composition pharmaceutique le contenant et son utilisation
WO2022199662A1 (fr) Composé polycyclique et son application
CN113429410A (zh) 多杂环取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途
CN113943275A (zh) 嘧啶类化合物及其用途
TW202112783A (zh) 三環類化合物及其用途
TW202128686A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
JP7574223B2 (ja) ＴＨＲ－βの調節物質およびその使用方法
WO2022237890A1 (fr) Composé à cycle fusionné du type azépine et son utilisation pharmaceutique
TWI855068B (zh) THR-β調節劑及其使用方法